Terry MB, et al. - Researchers investigated if risk-reducing salpingo-oophorectomy (RRSO) is efficacious in reducing the risk of breast cancer in this study. For this purpose, they evaluated a prospective cohort of 17,917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations) and followed the participants for a median duration of 10.7 years to examine the link between RRSO and breast cancer risk. Findings revealed, on modeling RRSO as a time-varying exposure, no link with breast cancer risk overall or by tertiles of predicted absolute risk based on family history or for BRCA1 and BRCA2 mutation carriers when examined separately. Even accounting for hormone therapy use after RRSO did not reveal any association. Overall, no efficacious role of RRSO in reducing breast cancer risk was evident.